<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2020-04-07T23:46:53Z"/>
<meta name="xmp:CreatorTool" content="Acrobat PDFMaker 15 for Word"/>
<meta name="Company" content="SA Health"/>
<meta name="Keywords" content="octreotide, Neonatal Medication Guideline, congenital chylothorax, hyperinsulinaemia, hyperinsulinaemic hypoglycaemia"/>
<meta name="subject" content="Neonatal Medication Guideline"/>
<meta name="dc:creator" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="dcterms:created" content="2020-04-07T23:46:51Z"/>
<meta name="Last-Modified" content="2020-04-07T23:46:53Z"/>
<meta name="dcterms:modified" content="2020-04-07T23:46:53Z"/>
<meta name="title" content="octreotide"/>
<meta name="Last-Save-Date" content="2020-04-07T23:46:53Z"/>
<meta name="meta:save-date" content="2020-04-07T23:46:53Z"/>
<meta name="dc:title" content="octreotide"/>
<meta name="modified" content="2020-04-07T23:46:53Z"/>
<meta name="cp:subject" content="Neonatal Medication Guideline"/>
<meta name="Content-Type" content="application/pdf"/>
<meta name="creator" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="meta:author" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="dc:subject" content="octreotide, Neonatal Medication Guideline, congenital chylothorax, hyperinsulinaemia, hyperinsulinaemic hypoglycaemia"/>
<meta name="meta:creation-date" content="2020-04-07T23:46:51Z"/>
<meta name="created" content="Wed Apr 08 09:16:51 ACST 2020"/>
<meta name="xmpTPg:NPages" content="2"/>
<meta name="Creation-Date" content="2020-04-07T23:46:51Z"/>
<meta name="SourceModified" content="D:20200406062109"/>
<meta name="meta:keyword" content="octreotide, Neonatal Medication Guideline, congenital chylothorax, hyperinsulinaemia, hyperinsulinaemic hypoglycaemia"/>
<meta name="Author" content="SA Maternal, Neonatal & Gynaecology Community of Practice"/>
<meta name="producer" content="Adobe PDF Library 15.0"/>
</head>
<body>
<pre>
South Australian Neonatal Medication Guidelines 

Octreotide 
100microgram/mL injection, 500microgram/mL injection 

  Department for Health and Wellbeing, Government of South Australia. All rights reserved. 
 

INFORMAL COPY WHEN PRINTED  Page 1 of 2 

Public-I4-A1 
 
 

Note:
This guideline provides advice of a general nature.  This statewide guideline has been prepared to promote and facilitate 
standardisation and consistency of practice, using a multidisciplinary approach.  The guideline is based on a review of 
published evidence and expert opinion.  
Information in this statewide guideline is current at the time of publication.  
SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not 
sponsor, approve or endorse materials on such links. 
Health practitioners in the South Australian public health sector are expected to review specific details of each patient and 
professionally assess the applicability of the relevant guideline to that clinical situation. 
If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the 
patient s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline. 
This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are 
responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful 
confidential discussion. This includes: 

  The use of interpreter services where necessary, 
  Advising consumers of their choice and ensuring informed consent is obtained, 
  Providing care within scope of practice, meeting all legislative requirements and maintaining standards of 

professional conduct, and  
  Documenting all care in accordance with mandatory and local requirements 

Dose and Indications 

Congenital Chylothorax 

Intravenous Infusion  

1 microgram/kg/hr, increased daily by 1 microgram/kg/hr up to 10 micrograms/kg/hr, if 
required. 

Higher doses of up to 20 microgram/kg/hour have been used in persistent chylothorax 

 

Refractory Hyperinsulinaemic Hypoglycaemia 
Consult a Paediatric Endocrinologist prior to use 

Intravenous Infusion 

0.2 to 1 microgram/kg/hr 

Preparation and Administration 

Intravenous Infusion  

Dilute the appropriate volume of octreotide (100 or 500 microgram/mL) using compatible fluid 
to a maximum concentration of 25micrograms/mL 

Infuse as a continuous infusion 

Compatible Fluids 
Sodium Chloride 0.9%, Glucose 5% 



South Australian Neonatal Medication Guidelines 

Octreotide 
 100microgram/mL injection, 500microgram/mL injection 
 

 

 
INFORMAL COPY WHEN PRINTED  Page 2 of 2 

Public-I4-A1 
 
 

Adverse Effects 
Common 

Flatulence, vomiting, diarrhoea, abdominal distension, hyperglycaemia, hypoglycaemia, 
hypothyroidism. 

Necrotising enterocolitis has been reported in term neonates administered octreotide 

Rare 

Hepatic dysfunction, bradycardia, steatorrhea 

Monitoring 
&gt; Blood glucose levels 

&gt; Signs and symptoms of necrotising enterocolitis 

&gt; Thyroid function 

Practice Points 
&gt; Avoid abrupt withdrawal of octreotide to avoid biliary colic and pancreatitis. Infusion can be 

gradually decreased over 2 to 7 days 

&gt; In refractory hyperinsulinaemic hypoglycaemia, tachyphylaxis to treatment may occur 
within several days 

References 
&gt; Saito M, Kamoda T, Kajikawa D et al, High Dose Octreotide for the Treatment of 

Chylothorax in Three Neonates, Journal of Neonatal Biology, 2016, vol 5, issue 2  
 
Document Ownership &amp; History 
Developed by: SA Maternal, Neonatal &amp; Gynaecology Community of Practice 
Contact: Health.NeoMed@sa.gov.au 
Endorsed by:  SA Health Safety and Quality Strategic Governance Committee 
Next review due:  03/04/2025 
ISBN number:  978-1-76083-177-6 
PDS reference:  CG228 
Policy history: Is this a new policy (V1)?  N 
 Does this policy amend or update and existing policy?   Y 
 If so, which version? V1 
 Does this policy replace another policy with a different title?  N 

Approval 
Date Version 

Who approved New/Revised 
Version Reason for Change 

03/04/2020 V2 
SA Health Commissioning and 
Performance Division 

Formal review. Higher dose 
recommendation for chylothorax 

19/04/2016 V1 
SA Health Safety and Quality Strategic 
Governance Committee 

Original SA Health Safety and Quality 
Strategic Governance Committee approved 
version 

 



</pre>
</body>
</html>